MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Gilead Sciences Inc.

Abierto

SectorSanidad

103.16 -3.7

Resumen

Variación precio

24h

Actual

Mínimo

100.88

Máximo

107.3

Métricas clave

By Trading Economics

Ingresos

530M

1.8B

Ventas

29M

7.6B

P/B

Media del Sector

274.553

57.333

BPA

1.9

Rentabilidad por dividendo

3.02

Margen de beneficios

23.557

Empleados

17,600

EBITDA

-655M

3.1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+9.79% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.02%

2.63%

Fecha Próximo Dividendo

26 jun 2025

Próxima Fecha de Ex Dividendo

13 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.7B

130B

Apertura anterior

106.86

Cierre anterior

103.16

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Gilead Sciences Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 20:17 UTC

Ganancias

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11 feb 2025, 21:17 UTC

Ganancias

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24 abr 2025, 20:08 UTC

Ganancias

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q Rev $6.67B >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q EPS $1.04 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q EPS $1.04 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q Net $1.32B >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24 abr 2025, 20:02 UTC

Ganancias

Gilead Sciences 1Q Rev $6.7B >GILD

11 abr 2025, 09:30 UTC

Principales Noticias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19 mar 2025, 14:50 UTC

Principales Noticias

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb 2025, 22:13 UTC

Charlas de Mercado
Ganancias

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 feb 2025, 21:06 UTC

Ganancias

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Raises Dividend 2.6%>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Comparación entre iguales

Cambio de precio

Gilead Sciences Inc. previsión

Precio Objetivo

By TipRanks

9.79% repunte

Estimación a 12 Meses

Media 116.79 USD  9.79%

Máximo 140 USD

Mínimo 89 USD

De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gilead Sciences Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

24 ratings

18

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

105 / 106.5Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.